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Merkel cell carcinoma (MCC) is a rare malignant neuro-
endocrine tumour of the skin (incidence: 0.2–0.45/105) 
that is more common in elderly, immunocompromised 
and HIV-infected individuals (1), with an overall 5-year 
survival rate: 30–60% (2). History of autoimmune con-
ditions such as rheumatoid or psoriatic arthritis has been 
connected to a slightly increased MCC risk (3). A recent 
breakthrough was the identification of a novel polyoma-
virus (MCPyV) in association with MCC pathogenesis 
(4). Various combination schemes of conventional anti-
neoplastic therapeutic modalities (surgery, radiotherapy 
and chemotherapy) are currently under evaluation for the 
treatment of metastatic MCC (2). Immunocryosurgery, 
i.e. liquid N2 cryosurgery sessions during continuing daily 
topical imiquimod application, has been introduced in 
our hospital for the treatment of basal cell carcinoma (5), 
lentigo maligna (6) and Bowen’s disease (7).
Herein, we report on the successful treatment with 
immunocryosurgery of a patient with a loco-regional 
in transit MCC recurrence that was heralded by the 
development of a paraneoplastic polyarthritis syndrome. 
CASE REPORT
An 84-year-old woman presented with a 2-week history of 
multiple (n = 11) cutaneous-subcutaneous nodules on her left 
tibia (Fig. 1a) and pain associated with local swelling of the 
right hip, right knee and both heels that precluded any move-
ment (Karnofsky score: 30). The patient was treated during 
the preceding week with 16 mg methylprednisolone/day. Six 
months prior, a MCC, 2.5 cm in diameter, was removed from 
the left calf (T2cN0M0; Stage IIB) and 2 months prior she was 
hospitalised with a 3-day history of generalised symmetrical 
polyarthritis. No recurrence of MCC was evident at that time; 
the symptoms were attributed to the exacerbation of a known 
psoriatic arthritis. Τhe patient was treated with tapered 16 mg 
methylprednisolone/day with prompt improvement.
During present hospitalisation laboratory evaluation was 
within normal limits except for increased erythrocyte sedi-
mentation rate (94 mm/h), C-reactive protein (289 mg/l), a 
very low titre of rheumatoid factor (1/20, latex fixation test) 
and a low titre of antinuclear antibodies (1/160, indirect im-
munofluorescence); antibodies to extractable nuclear antigens 
and to double-stranded DNA, C3 and C4 complement levels and 
anti-cyclic citrullinated antibodies were within normal limits. 
Synovial fluid aspirate from the right knee supported the diag-
nosis inflammatory arthritis (30,000 leucocytes/mm3 with 90% 
neutrophils; no malignant cells; no crystals; negative cultures).
Biopsy of a nodule confirmed the recurrence of MCC. By 
immunohistochemistry (8) almost all tumour cells were positive 
for the large T-antigen of the MCPyV (antibody CM2B4, Santa 
Cruz Biotechnology Inc., sc-136172; Fig. S1e1). Chest X-ray, 
abdomen ultrasound and CT scans of chest and abdomen did not 
show any lymph node or organ metastases. The constellation of 
physical, laboratory and radiologic findings set the diagnosis of 
in transit recurrence of MCC (T2N2M0; stage IIIB (2)) heralded 
by arthritis of putatively paraneoplastic origin.
Because of the markedly reduced general state of the patient 
all conventional treatment options (surgery, radiotherapy, chemo-
therapy) were postponed. Faced with a rapidly progressing tumour 
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Fig. 1. Treatment of in transit recurrence of Merkel cell carcinoma with 
immunocryosurgery. A: Detail of recurrence basin (left tibia) at baseline, 
showing 6 clinically evident metastases (arrows). B: At the end of the 
immunocryosurgery treatment cycle (1 week after stopping imiquimod 
application; 4 weeks after a single session of cryosurgery) of the 2 lesions 
to the right (arrow). C: Outcome 6 months after the end of the last treatment 
cycle. Complete regression of tumours is evident. 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1812
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we decided for palliative immunocryosurgery. As methylpred-
nisolone was tapered within 2 weeks to 4 mg/day, standard im-
munocryosurgery (5–7) was initiated with imiquimod once daily 
and two-weekly cryosurgery sessions (2×15 s active freezing/
tumour) in 3–5 lesions each time. Already 4 weeks after the first 
cryosurgery session substantial remission of treated metastases 
was evident (Fig. 1b). Imiquimod was continued on each cryo-
surgery treated site for an additional 3 weeks and therapy was 
initiated on newly emerging metastases. A total of 16 lesions were 
treated in a period of 3 months. Except for local redness, irrita-
tion and oozing (5–7) no other local or systemic adverse effects 
were observed during treatment. Healing was excellent and no 
new lesions emerged during 9 months post-treatment (Fig 1c). 
Only the anticipated protracted healing of cryosurgery sites in the 
lower third of the tibia was evident. In parallel joint complaints 
subsided completely and the patient regained adequate mobility 
without analgesics or corticosteroids (Karnofsky score: 50). 
DISCUSSION
We describe the effective immunocryosurgery treat-
ment of an in transit MCC recurrence associated with 
polyarthritis. Arthritis is common in patients with ma-
lignancies and may have diverse aetiologies (septic, 
crystal-induced, drug-induced, metastatic or paraneo-
plastic) (9). Paraneoplastic polyarthritis associated with 
solid tumours and haematological malignancies usually 
(88.5%) appears prior (mean latency: 3.6 months) to 
the diagnosis of the tumour (10). Possible mechanisms 
of paraneoplastic polyarthritis include an immune 
complex-mediated synovitis, cross-reactivity of antige-
nic determinants on the synovium and neoplastic tissue 
and abnormalities of cell-mediated immunity (11). The 
polyarthritis of this patient, which emerged 2 months 
before tumour relapse and subsided in parallel to tumour 
control, may represent the first description of paraneo­
plastic arthritis in association with MCC recurrence.
Regarding the assessment of the therapeutic efficacy 
of immunocryosurgery in MCC, topical imiquimod has 
been evaluated in a single case of MCC in combina-
tion with radiotherapy (12) and complete remission 
for 7 years of a primary T2 MCC was described with 
cryosurgery (13). Before the observed therapeutic 
outcome can be ascribed to immunocryosurgery one 
should consider the possibility of spontaneous regres-
sion. MCC is characterised by a marked potential for 
spontaneous regression, sometimes seemingly induced 
by ‘traumatic’tumour manipulations (14). However 
spontaneous regression is rather unlikely in our case, 
as only treated lesions regressed each time and new 
ones appeared in the interim. Immunocryosurgery was 
designed to induce antitumour immunity (5, 6) and 
tumour infiltration by CD8+ cells is observed during 
clearance of basal cell carcinoma treated with this mo-
dality (unpublished data). Likewise, MCC is a strongly 
immunogenic tumour per se with cases of spontaneous 
regression being associated with intratumoural efflux 
of CD8+ effector cells (15).
Our current observation of immunocryosurgery in-
duced remission in this patient with stage IIIB MCC is 
an encouraging outcome to be explored in future cases. 
The cessation of arthritis following tumour remission 
not only supports its paraneoplastic nature in this case, 
but might also be a sign of adequate tumour control. 
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